Abaimov D A, Kovalev G I
Eksp Klin Farmakol. 2007 Jul-Aug;70(4):11-4.
The ex vivo effects of the new antiparkinsonian drug (adamantane derivative) hemantane on the [3H]-dopamine reuptake rate (V) in striatum have been studied upon acute and subchronic administration of the drug in Wistar rats. The [3H]-dopamine reuptake was measured in striatal synaptosomes isolated from rats decapitated 1 hour after drug injection (40 mg/kg, i.p.), and in synaptosomes of rats treated for 7 days with hemantane (single daily dose, 20 mg/kg, i.p.). The acute experiment resulted in a significant (30%) decrease in the apparent Vmax of [3H]-dopamine reuptake, while the value of the apparent Km remained unchanged. The data obtained indicate that hemantane suppresses the DA transporter function within physiological concentration range via noncompetitive mode. In contrast, subchronic drug administration increases by 17% the apparent Vmax. These results demonstrate the active participation of presynaptic transport mechanism in dopamine-positive effects of hemantane.
在Wistar大鼠中,在急性和亚慢性给予新型抗帕金森病药物(金刚烷衍生物)海曼烷后,研究了其对纹状体中[3H] - 多巴胺再摄取率(V)的离体效应。在注射药物(40mg / kg,腹腔注射)1小时后断头的大鼠分离出的纹状体突触体中,以及用海曼烷(每日单次剂量,20mg / kg,腹腔注射)处理7天的大鼠的突触体中测量[3H] - 多巴胺再摄取。急性实验导致[3H] - 多巴胺再摄取的表观Vmax显著降低(30%),而表观Km值保持不变。获得的数据表明,海曼烷在生理浓度范围内通过非竞争性模式抑制DA转运体功能。相反,亚慢性给药使表观Vmax增加17%。这些结果证明了突触前转运机制在海曼烷的多巴胺阳性效应中的积极参与。